ABSTRACT
AIMS: Post-renal-transplanted patients frequently present hyperglycemia immediately after the procedure. The goal of this work was to evaluate the effect of linagliptinâ¯+â¯insulin in post-renal-transplanted patients with hyperglycemia. METHODS: Retrospective comparative study in post-renal transplanted patients with hyperglycemia after transplantation who were treated with linagliptin 5â¯mg daily plus insulin vs insulin alone for 5â¯days after renal transplantation with hyperglycemia. Main outcomes were glucose levels, insulin dose and severity of hypoglycemia. RESULTS: There were 14 patients treated with linagliptinâ¯+â¯insulin and 14 patients treated only with insulin. Glucose levels and insulin doses were lower in the linagliptinâ¯+â¯insulin group in comparison with the insulin alone group, 131.0⯱â¯15.1 vs 191.1⯱â¯22.5â¯mg/dl (7.27⯱â¯0.84 vs 10.61⯱â¯1.25â¯mmol/l) and 37.5⯱â¯6.3 vs 24.2⯱â¯6.6 U, respectively (pâ¯<â¯0.05). Hypoglycemia was less severe in the linagliptinâ¯+â¯insulin group, 65.1⯱â¯2.2 vs 54.2⯱â¯3.3â¯mg/dl (3.61⯱â¯0.12 vs 3.00⯱â¯3.3⯱â¯0.18â¯mmol/l), p 0.036. CONCLUSIONS: The combination of linagliptinâ¯+â¯insulin provided better glycemic control with a lower insulin dose and less severe hypoglycemia in comparison to insulin alone in patients with hyperglycemia immediately after renal transplantation.
